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Background/objective: Some locally advanced rectal cancer (LARC) patients treated with neoadjuvant
chemoradiotherapy (CRT) prior to total mesorectal excision (TME) show early recurrence with a short
disease-free interval. This is unacceptable for patients and their families, necessitating re-evaluation of
the treatment process. We aimed to evaluate the risk factors and prognostic impact of early recurrence in
patients who received preoperative CRT (pCRT) followed by TME for LARC.
Methods: Of 714 patients who underwent curative resection after pCRT for LARC from January 2010 to
December 2016, we included 139 who developed recurrence after resection. Patients were divided into
an early recurrence group, diagnosed <12 months after primary surgery, and a late recurrence group,
diagnosed 12 months after primary surgery.
Results: Forty-nine patients experienced early recurrence and 90 experienced late recurrence. Multi-
variate analysis revealed that tumor regression grade (hazard ratio [HR] 2.962, 95% confidence interval
[CI] 1.434e6.119, P ¼ 0.003) and positive ypN stage (HR 2.110, 95% CI 1.144e3.892, P ¼ 0.017) correlated
with early recurrence. The 5-year overall survival rates for early and late recurrences were not signifi-
cantly different (P ¼ 0.121).
Conclusion: In patients with early recurrence after pCRT followed by TME, tumor regression grade and
ypN stage positivity were independent predictors of the early recurrence.
© 2020 Asian Surgical Association and Taiwan Robotic Surgery Association. Publishing services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Patients with locally advanced rectal cancer (LARC) are treated
with neoadjuvant chemoradiotherapy (CRT) prior to total meso-
rectal excision (TME) to increase the likelihood of inducing tumor
regression, achieve a negative margin, and reduce the risk of local
recurrence. Postoperative adjuvant chemotherapy is also recom-
mended to reduce the risk of distant metastasis. These treatments
not only maintain high levels of local tumor control but also result
in long-term survival.1,2
Nevertheless, recurrence after perioperative CRT and curative
surgery has been reported to be between 25% and 40% in LARC,verance Hospital Yonsei Uni-
un-ku, Seoul 03722, South
an Robotic Surgery Association. Pu
c-nd/4.0/).
us User (n/a) at Yonsei University Co
 use only. No other uses without permdepending on the progression of the initial pathological stage of the
disease and difference in follow-up period.3,4 In particular, distant
metastasis is the most common cause of death in LARC patients.5
The lung is the most common organ for metastasis in rectal can-
cer, followed by the liver.6 Early recurrences within 1 year after
surgery for primary rectal cancer have been linked to poor sur-
vival.3,7 Thesemay exist asmicrometastatic foci at the time of initial
diagnosis.8
Early recurrence after completion of scheduled treatment is
extremely discouraging for patients and their family members as
this indicates that the cancer may be too difficult to treat. As
mentioned earlier, a short interval to disease progression may
reflect aggressive biological behavior and poor oncological
outcomes.
In this situation, the current standard guidelines for the treat-
ment of LARC are revisited. Patients with poor response after
completion of preoperative CRT usually undergo surgery once anblishing services by Elsevier B.V. This is an open access article under the CC BY-NC-
llege of Medicine from ClinicalKey.com by Elsevier on April 
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This study aimed to investigate the risk factors and prognostic
factors associated with early recurrence in LARC patients who
received preoperative chemoradiotherapy (pCRT) in combination
with TME.(&12 months, n ¼ 49) (>12 months, n ¼ 90)
Age (years) 0.778
<60 26 (53.1%) 50 (55.6%)
60 23 (46.9%) 40 (44.4%)
Gender, n (%) 0.940
Male 34 (69.4%) 63 (70.0%)
Female 15 (30.6%) 27 (30.0%)
BMI (kg/m2) 25 15 (30.6%) 18 (20.0%) 0.160
preCEA (ng/mL) 5 21 (42.9%) 44 (48.9%) 0.496
Sphincter preservation 0.134
No 0 (0.0%) 4 (4.4%)
Yes 49 (100.0%) 86 (95.6%)
Distance from AV (cm) 0.327
Low 16 (32.7%) 37 (41.1%)
Mid/Upper 33 (67.3%) 53 (58.9%)
mrT stage S T3 21 (42.9%) 46 (51.1%) 0.352
mrN (þ) 39 (79.6%) 73 (81.1%) 0.829
mrCRM (þ) 23 (46.9%) 39 (43.3%) 0.683
mrEMVI(þ) 16 (32.7%) 37 (41.1%) 0.327
Adjuvant CTx. 42 (85.7%) 82 (91.1%) 0.327
BMI: body mass index, preCEA: preoperative carcinoembryonic antigen, AV: Anal
verge, scular invasion, mrCRM: MRI circumferential resection margin, mrEMVI: MRI
extramural vascular invasion, CTx: chemotherapy.2. Methods
Between January 2010 and December 2016, 714 LARC patients
who underwent curative resection after preoperative CRT at our
institutionwere reviewed. Patientswith distantmetastasis at initial
diagnosis or at the work-up stage after preoperative CRT were
excluded. Patients who did not undergo preoperative CRTwere also
excluded. Among the patients included in the study, there were 139
recurrences, which accounted for 19.5%. Among them, the group
with recurrence within 1 year after surgery, defined as early
recurrence, included 49 patients (early recurrence group). In the
remaining 90 patients, recurrence occurred 1 year or more after
surgery, and this was defined as late recurrence (late recurrence
group). This study was retrospective in design and received
approval from our internal review board at Severance Hospital (IRB
No. 4-2019-1080).
In the case of neoadjuvant chemoradiotherapy in our institu-
tion, among patients with rectal cancer, T3 or T4 stage disease or
clinically positive metastatic lymph node was selected after review
of imaging study by multidisciplinary tumor board. The total dose
of RT was 50.4 Gy in 28 fractions, and capecitabine was given at an
oral dosage of 825 mg/m2 bid on each day of the radiotherapy
period with the first daily dose applied 2 h before irradiation. About
6 weeks after the completion of neoadjuvant chemoradiotherapy,
the response was evaluated, and TMEwas administered 1e2 weeks
later.
In our institution, all LARC patients visited outpatients at least 4
times a year for 2 years after surgery, followed by 2 times a year
between 2 and 5 years after surgery. We have been following
outpatient follow-up for 5 years unless there is a special event. The
samemethod was applied to the 714 patients in this study and only
those with at least one year of outpatient follow-up were included.
Statistical analyses were performed using IBM SPSS Statistics
ver. 25.0 (IBM Corp., Armonk, NY, USA). Differences between the
groups were tested with chi-squared tests. Overall survival was
estimated using the Kaplan-Meier method, and univariate analyses
of the significance of prognostic factors were evaluated using the
log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs)
were estimated using Cox regression models. Multivariate analysis
of factors associated with recurrence rate was performed using the
Cox proportional hazards model with the backward stepwise
(likelihood ratio) method. Variables with P values < 0.05 on the
univariate analysis were included in the final multivariable model.
A P value  0.05 was considered statistically significant.3. Results
3.1. Patient characteristics
The characteristics of 139 patients with LARC recurrence are
summarized in Table 1. Patients with early recurrence (n¼ 49) were
compared with patients with late recurrence (n ¼ 90). Age, sex,
body mass index, preoperative carcinoembryonic antigen level,
tumor location, sphincter preservation, pre-treatment mrT classi-
fication and mrN status, circumferential resection margin (CRM)
status, extramural vascular invasion (EMVI) status, and adjuvant
chemotherapy were not different between the two groups.Downloaded for Anonymous User (n/a) at Yonsei University Colleg
15, 2021. For personal use only. No other uses without permissi3.2. Pathological outcomes
Table 2 shows the pathological outcomes between the early and
late recurrence groups. In both groups, well or moderate differen-
tiationwas most common, but this was not a statistically significant
difference. In terms of tumor regression grade, 39 patients (79.6%)
had a poor response in the early recurrence group compared with
74.4% in the late recurrence group, but this difference was not
statistically significant. Perineural invasion and lymphovascular
invasion were not significantly different between the two groups.
3.3. Patterns of recurrence
Recurrence of rectal cancer can be divided into local recurrence
and systemic recurrence. Local recurrence occurred in 11.1% of the
late recurrence group but not in the early recurrence group. The
occurrence of systemic recurrence was not significantly different in
the two groups, but local and systemic recurrences were much
higher in the early recurrence group than in the late recurrence
group. In the early recurrence group, all 49 patients showed a
systemic recurrence pattern. The results are shown in Table 3.
3.4. Site of systemic recurrence
Table 4 compares the sites of systemic recurrence in both
groups. Lung metastasis was the most common in both groups,
followed by liver metastasis. Transition to the peritoneum, brain,
and bone tended to be about twice as likely in the early recurrence
group than that in the late recurrence group.
3.5. Factors associated with early recurrence
In the univariate analysis, the risk factors for early recurrence
were lymphovascular invasion, perineural invasion, clinical EMVI,
ypT stage 3 ormore and n stage positive, pathological CRM positive,
and tumor regression grade 3 or more. Multivariate analysis was
performed with the univariate analysis factors and a P-value
threshold of 0.05. A positive ypN stage (HR 2.110, CI 1.144e3.892,e of Medicine from ClinicalKey.com by Elsevier on April 





(<12 months, n ¼ 49) (S12 months, n ¼ 90)
Differentiation 0.665
WD/MD 46 (93.9%) 87 (96.7%)
PD/Mucinous 3 (6.1%) 3 (3.3%)
Tumor regression grade 0.496
TRG 1-2 10 (20.4%) 23 (25.6%)
TRG 3-5 39 (79.6%) 67 (74.4%)
ypT stage 0.456
pCR-2 16 (32.7%) 24 (26.7%)
T3-4 33 (67.3%) 66 (73.3%)
ypN stage 0.192
N0 28 (57.1%) 41 (45.6%)
N1-2 21 (42.9%) 49 (54.4%)
CRM (1.0 mm) 8 (16.3%) 10 (11.1%) 0.382
Margin involvement 1 (2.1%) 0 (0.0%) 0.353
Perineural invasion 5 (10.2%) 11 (12.2%) 0.722
Lymphovascular invasion 9 (18.4%) 13 (14.4%) 0.545




Early Late P ¼ 0.013
(<12 months, n ¼ 49) (S12 months, n ¼ 90)
Local only 0 (0%) 10 (11.1%)
Local þ Systemic 16 (32.7%) 18 (20.0%)
Systemic only 33 (67.3%) 62 (68.9%)
Table 4
Site of systemic recurrence.
Recurrence site Recurrence
Early Late
(<12 months) (S12 months)
Liver 18 (37.5%) 29 (31.9%)
Lung 29 (60.4%) 51 (56.0%)
Extra-abdominal LN 1 (2.1%) 1 (1.1%)
Intra-abdominal LN 3 (6.3%) 3 (3.3%)
Peritoneum 3 (6.3%) 2 (2.2%)
Brain 4 (8.3%) 2 (2.2%)
Adrenal 1 (2.1%) 2 (2.2%)
Pancreas 0 (0.0%) 1 (1.1%)
Bone 3 (6.3%) 3 (3.3%)
H.-G. Kim et al. / Asian Journal of Surgery 44 (2021) 298e302300P ¼ 0.017) and tumor regression grade of 3 or more (HR 2.962, CI
1.434e6.119, P ¼ 0.003) showed statistically significant results. The
results are shown in Table 5.
3.6. Overall survival per recurrence group
A Kaplan-Meier curve comparing overall survival in the early
and late recurrence groups is shown in Fig. 1. Although the P-value
was 0.121 and no significant results were obtained, the overall
survival at 3 years after surgery was 76.8% in the early recurrence
group and 90.8% in the late recurrence group.
4. Discussion
In this study, we did not find any difference in the baseline
characteristics or pathological outcomes in patients in the early andDownloaded for Anonymous User (n/a) at Yonsei University Co
15, 2021. For personal use only. No other uses without permlate recurrence groups. However, all patients in the early recur-
rence group showed a systemic recurrence pattern, which was
observed a higher rate than that in the patients in the late recur-
rence group.
Despite significant advances in the management of LARC,
recurrence still occurs. With the advancement of surgical technol-
ogy, radiotherapy to reduce the possibility of local recurrence and
preoperative chemotherapy have resulted in much lower recur-
rence rates in recent years. In spite of this, recurrence remains a
highly morbid, debilitating condition. Past studies have reported
recurrence rates of up to 40% after curative treatment for rectal
cancer.9,10 However, the recently introduced National Compre-
hensive Cancer Network guidelines reported a recurrence rate of
20.8%, which is similar to the recurrence rate of 20.0% in our LARC
patients.6 This recurrence rate is still high, and notable efforts are
being made to lower it.
Many studies reported that systemic recurrence has a poorer
prognosis than local recurrence in patients with rectal cancer after
curative resection.11e13 In this study, although no statistically sig-
nificant difference was found between the two groups, the 3-year
overall survival rate of 76.8% in the early recurrence group was
somewhat lower than that of 90.8% in the late recurrence group.
This may be attributed to the earlier onset of recurrence, but it also
disproves the more systemic recurrence pattern in the early
recurrence group. Because the number of patients in this study was
not sufficiently large, it is believed that the survival rate does not
show statistically significant results. However, since the tendency
was confirmed in this study, a meaningful result will be obtained if
more patients are analyzed in the future or supplemented with
multicenter studies.
In this study, we identified that the lung was the most common
systemic recurrence site in both early and late recurrence groups of
LARC patients. Unlike the liver, which is generally known to be the
distant metastasis site of colorectal cancer, all patients included in
this study had rectal cancer, and lymphatic fluid drains directly to
the lung through the lateral pathway.14,15 In addition, the distant
metastasis of rectal cancer, which shows a higher proportion of
lung metastasis than liver metastasis, can be explained as hema-
togeneous metastasis by bypassing the liver via direct venous
drainage into the vena cava.16e18
Early recurrence can be divided into two categories: the first
includes cases without metastasis at the time of diagnosis andllege of Medicine from ClinicalKey.com by Elsevier on April 
ission. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 5
Uni- and multivariate analysis of risk factors associated with early recurrence using cox regression model.
Factors Early Recurrence
Univariate Multivariate
P HR 95% CI P
Age (<60 vs. 60 years) 0.886
Gender (male vs. female) 0.556
BMI (<25 vs. 25 kg/m2) 0.376
preCEA (<5 vs. 5 ng/mL) 0.071
LVI 0.004
PNI 0.035




Resection margin (þ) 0.236
Histology (WD/MD vs. PD/Mucinous) 0.655
ypT stage (T0-2 vs. T3-4) 0.002
ypN stage (N0 vs. N1-2) 0.002 2.110 1.144e3.892 0.017
Pathologic CRM (þ) 0.003
TRG (12 vs. 345) 0.001 2.962 1.434e6.119 0.003
Adjuvant CTx (Yes vs. No) 0.694
BMI: body mass index, preCEA: preoperative carcinoembryonic antigen, LVI: lymphovascular invasion, PNI: perineural invasion, cEMVI: clinical extramural vascular invasion,
cCRM: clinical circumferential resection margin. WD: well differentiated, MD: moderately differentiated, PD: poorly differentiated, pTNM: AJCC pathologic staging 7th edi-
tion,TRG: Mandard tumor regression grade, HR: hazard ratio, 95% CI: 95% confidence interval.
Fig. 1. KM analysis for overall survival per recurrence group.
H.-G. Kim et al. / Asian Journal of Surgery 44 (2021) 298e302 301surgery, and the second includes cases where metastasis has
already been detected at the time of diagnosis. However, given the
small size of the metastasis, it is not detected on abdominopelvic
and chest computed tomography, magnetic resonance imaging, and
even positron emission tomography-computed tomography during
work-up.8 In the future, when the development of diagnostic
methods enables the examination of metastatic lesions smaller
than the current smallest size that can be evaluated, metastasis can
be confirmed at the time of diagnosis and other treatments can be
performed. However, the current treatment is not sufficient for
patients in the early recurrence group in whommetastasis is found
within 12 months after surgery.
Since the 1990s, fluorouracil plus leucovorin as a neoadjuvantDownloaded for Anonymous User (n/a) at Yonsei University Colleg
15, 2021. For personal use only. No other uses without permissichemoradiation therapy and preoperative radiation therapy with a
total dose of 5040 cGy have had a significant effect on improving
local control and survival in LARC patients. It is considered a gold
standard and has been around for almost 30 years.19,20 The purpose
of neoadjuvant long-course chemoradiation is to enable R0 resec-
tion with tumor shrinkage. Although local control has been
improved because of these treatments, it is necessary to obtain
better results by changing to a more effective schedule of preop-
erative treatment. Treatment of rectal cancer over the past 30 years
has gradually lowered local recurrence rates owing to better im-
aging of localized and systemic diseases and improved surgical
techniques. There has also been development of radiation tech-
niques and chemotherapy regimens. In addition, non-surgicale of Medicine from ClinicalKey.com by Elsevier on April 
on. Copyright ©2021. Elsevier Inc. All rights reserved.
H.-G. Kim et al. / Asian Journal of Surgery 44 (2021) 298e302302treatment in patients with a complete clinical response after pCRT
has been routinely accepted in patients requiring abdominoper-
ineal resection. These changes led to the development of a treat-
ment called total neoadjuvant therapy, wherein the treatment
which is usually administered as postoperative (adjuvant) chemo-
therapy is shifted to the preoperative setting.21,22 Despite our wide
understanding of biology and accurate imaging for rectal cancer, a
variable range of treatment outcomes remains; hence, we need to
plan more tailored treatment strategies based on the patient’s
subcategory.
Recently, consolidation chemotherapy after short-course
radiotherapy has been introduced as a treatment method. Ac-
cording to Bojko et al, patients received preoperative 5  5 Gy
irradiation over 5 dayswith consolidation chemotherapy consisting
of three cycles of FOLFOX4. The short-term outcome was better,
acute toxicity was lower, and no difference was found in post-
operative complications compared with conventional treatment.23
The RAPIDO trial was similar, but the chemotherapy administered
was slightly different, wherein short-course radiotherapy
(5 Gy  5) was followed by full-dose chemotherapy (capecitabine
and oxaliplatin) over six cycles before surgery.24,25
In this study, we did not find any risk factors present at the time
of diagnosis that were associated with the possibility of early
recurrence. Pathological low tumor regression grade and ypN stage
positivity were found to be independent risk factors in the early
recurrence group compared with the non-recurrence group. There
is no way to determine the risk factors for early recurrence at
diagnosis or before surgery. Moreover, pathological low tumor
regression grade and ypN stage positivity are present after surgery;
thus, frequent and close follow-up with adjuvant chemotherapy is
necessary to determine recurrence within 1 year after surgery.
Further research is needed to identify risk factors that can predict
early recurrence after diagnosis and before neoadjuvant treatment
begins.
This study had several limitations. First, this study was a
retrospective analysis of a single institution in Korea, and all pa-
tients were Asian, reducing the generalizability of our results. On
the other hand, almost all patients received postoperative follow-
up at our hospital, which is a major advantage. Second, we still
have not found a factor that predicts early recurrence at the time of
diagnosis. If we could predict recurrence at the time of diagnosis,
this might improve the survival rate, as we could attempt different
treatments.
Our findings may contribute to a more prolonged disease-free
interval for these patients. First, we must identify patients who
are at risk of early recurrence before starting treatment or restaging
after neoadjuvant chemoradiation. Then, current standard treat-
ment schedulesmay be changed in sequence in this high-risk group
of patients.
In conclusion, in LARC patients who received pCRT followed by
TME, tumor regression grade and ypN stage positivity were inde-
pendent predictors of early recurrence. Although early recurrence
was not predictable before pCRT, poor responders (low tumor
regression grade) and those with ypN stage positivity need more
careful monitoring owing to the possibility of early recurrence.
Conventional neoadjuvant chemoradiation may not be enough to
treat patients with this early recurrence pattern. Therefore,
different treatments such as total neoadjuvant treatment and
consolidation chemotherapy are necessary, and further research is
needed to develop alternative treatment methods.
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